Logo image
Back
The patient centric development of an inclusive multi-arm multi-stage trial for Parkinson disease
Journal article   Open access   Peer reviewed

The patient centric development of an inclusive multi-arm multi-stage trial for Parkinson disease

Marie-Louise Zeissler, Matthew Burnell, Thomas R Barber, Yoav Ben-Shlomo, Caroline S Clarke, Sally Collins, Carl Counsell, Joy Duffen, Mark J Edwards, Romy Ellis-Doyle, …
Brain communications, v 8(5), Forthcoming
22 Sep 2026
DOI: https://doi.org/10.1093/braincomms/fcag349
url
https://doi.org/10.1093/braincomms/fcag349View
Published, Version of Record (VoR) Open

Abstract

Parkinson's disease trial design multi-arm multi-stage patient and public involvement and engagement
There is an urgent need to speed up clinical trials for potential disease-modifying therapies that slow progression of Parkinson’s disease. The Edmond J Safra Accelerating Clinical Trials in Parkinson’s Disease (EJS ACT-PD) initiative set out to develop a patient-centric and inclusive platform trial using an innovative multi-arm, multi-stage (MAMS) design. We describe the work of the EJS ACT-PD consortium, which included over 90 experts including people with Parkinson’s disease and care partners across six working groups. There were 5 key challenges: developing an efficient MAMS trial that meets regulatory requirements and is acceptable to people with Parkinson’s; mitigating participant heterogeneity; reducing the risk of simultaneous arm closures; introducing different treatment regimens into a MAMS trial; and maximising deliverability and accessibility of a MAMS trial. The final design was achieved through an iterative process and critical appraisal of data modelling exploring the impact of participant numbers per arm, trial durations and endpoints. Every aspect of the design was informed by people with Parkinson’s disease and care partners whose advice ensured acceptability, deliverability and accessibility. The EJS ACT-PD trial will start with one placebo and three treatment arms, each with 400 participants, with a primary endpoint at three years powered to detect a 30% reduction in rate of progression of MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part I and II summed scores. Interim analyses will test for activity using the summed inverse variance weighted MDS-UPDRS Part I, II and remote part III scores. Ineffective arms will be closed, allowing participants to be re-randomised. Cost-effectiveness analysis is embedded. Further promising treatments will be added in future arms, subject to additional funding. To maximise accessibility and inclusivity, the trial will allow for study visits to be conducted remotely based on participant preference. National sites were selected to maximise accessibility and inclusive recruitment with core funded staff placed within experienced trial sites to support training and delivery at less experienced centres. By involving people with Parkinson’s and care partners as well as stakeholders with broad scientific expertise, we have developed an inclusive MAMS trial which captures all stages of disease with partial remote delivery and clear design rationales that will significantly speed up the testing of disease modifying therapies in Parkinson’s disease.

Metrics

1 Record Views

Details

Logo image